{
    "symbol": "TNDM",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-03 23:02:05",
    "content": " All are progressing well and a few highlights since the last call include: enrollment for our type 2 feasibility study for Control-IQ is now complete; the extension phase for the pediatric trial using Control-IQ has recently wrapped up and data will be compiled over the next few months to support regulatory filings to pursue an age indication for children younger than 6 years old; and lastly, we've now initiated a study using Control-IQ with Ninja to expand the insulin indications and provide additional choice to our customers."
}